يعرض 1 - 20 نتائج من 48 نتيجة بحث عن '"K. Rickard"', وقت الاستعلام: 0.58s تنقيح النتائج
  1. 1
    Ensifentrine Reduced Healthcare Resource Utilization in Subjects With COPD: Results From Enhance-2, a Phase 3 Trial of Ensifentrine, a Dual PDE3/4 Inhibitor

    المؤلفون: I. Barjaktarevic, T. Rheault, T. Bengtsson, K. Rickard

    المصدر: B22. NEW TREATMENTS AND NOVEL TARGETS FOR COPD AND ALPHA-1.

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::b7888573f52608edb291b5fa3540b7a5
    https://doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2839

    View record in OpenAIRE

    أضف إلى المفضلة
  2. 2
    Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Improves Lung Function and Reduces Exacerbation Rate and Risk in Phase 3 Enhance-2 Trial

    المؤلفون: A. Anzueto, I. Barjaktarevic, T. Rheault, T. Bengtsson, K. Rickard

    المصدر: C15. EMERGING COPD DIAGNOSTICS AND TREATMENTS.

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::a4dec7474a5b480083ac206bbd74160c
    https://doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a4494

    View record in OpenAIRE

    أضف إلى المفضلة
  3. 3
    Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, in Moderate and Severe COPD: Symptoms, Quality of Life and Health Status From the Phase 3 Trial Enhance-2

    المؤلفون: T. Rheault, T. Bengtsson, K. Rickard

    المصدر: C40. CLINICAL TRIALS AND NOVEL INTERVENTIONS IN COPD.

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::b2bc56b4bc253552f30590605b36853a
    https://doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5000

    View record in OpenAIRE

    أضف إلى المفضلة
  4. 4
    Twice-daily, Nebulized Ensifentrine Produced Significant Improvement in Week 12 Lung Function: Sub-group Analysis in the Phase 3 Trial Enhance-2

    المؤلفون: K. Rickard, T. Bengtsson, T. Rheault

    المصدر: B22. NEW TREATMENTS AND NOVEL TARGETS FOR COPD AND ALPHA-1.

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::58d8f7bfb000135e34f2f0aa007d42a2
    https://doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2838

    View record in OpenAIRE

    أضف إلى المفضلة
  5. 5
    Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Significantly Improves COPD Symptoms and Quality of Life in the Phase 3 Enhance-1 Trial

    المؤلفون: F.C. Sciurba, T. Rheault, T. Bengtsson, K. Rickard

    المصدر: C40. CLINICAL TRIALS AND NOVEL INTERVENTIONS IN COPD.

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::bfb88b03c00b4900b0ab191b4a97a310
    https://doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5007

    View record in OpenAIRE

    أضف إلى المفضلة
  6. 6
    Ensifentrine, a Dual Inhibitor of PDE3 and PDE4, Reduces the Risk of Exacerbation Regardless of Background Medication Use: A Sub-group Analysis of ENHANCE-2, a Phase 3 Trial

    المؤلفون: G.T. Ferguson, T. Rheault, T. Bengtsson, K. Rickard

    المصدر: C40. CLINICAL TRIALS AND NOVEL INTERVENTIONS IN COPD.

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::18220ebd0bef0301c448280c228c8178
    https://doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a4999

    View record in OpenAIRE

    أضف إلى المفضلة
  7. 7
    Safety Results From Dual PDE3/4 Inhibitor Ensifentrine: Gastrointestinal and Cardiovascular Safety From a 24-week Phase 3 Trial, Enhance-2

    المؤلفون: T.M. Siler, K. Rickard, T. Bengtsson, T. Rheault

    المصدر: C40. CLINICAL TRIALS AND NOVEL INTERVENTIONS IN COPD.

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::16e0e4d084dd0c96c46d1420857f9fd0
    https://doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5003

    View record in OpenAIRE

    أضف إلى المفضلة
  8. 8
    Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Significantly Reduces Annualized Exacerbations and Delays the Time to First Exacerbation in COPD: Pooled Sub-Group Analyses of Enhance-1 and Enhance-2 Phase 3 Trials

    المؤلفون: I. Barjaktarevic, T. Rheault, T. Bengtsson, K. Rickard

    المصدر: C40. CLINICAL TRIALS AND NOVEL INTERVENTIONS IN COPD.

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::bf061c724278623a6f4cd5e4ca52e647
    https://doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5008

    View record in OpenAIRE

    أضف إلى المفضلة
  9. 9
    Treatment With Ensifentrine, a Dual PDE3 and PDE4 Inhibitor, Significantly Reduced Exacerbation Rate and Risk in Subjects With COPD: Sub-group Results From the Phase 3 Trial, Enhance-2

    المؤلفون: A. Anzueto, T. Rheault, T. Bengtsson, K. Rickard

    المصدر: C40. CLINICAL TRIALS AND NOVEL INTERVENTIONS IN COPD.

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::565143ce172479a6d861b9a491cf9e11
    https://doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a4998

    View record in OpenAIRE

    أضف إلى المفضلة
  10. 10
    Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Improves Lung Function, Symptoms, Quality of Life and Reduces Exacerbation Rate and Risk in Patients With COPD: Results From Replicate Phase 3 Trials

    المؤلفون: F.C. Sciurba, A. Anzueto, T. Rheault, T. Bengtsson, K. Rickard

    المصدر: C40. CLINICAL TRIALS AND NOVEL INTERVENTIONS IN COPD.

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::83efdd25584249f1af637b1415e34925
    https://doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5005

    View record in OpenAIRE

    أضف إلى المفضلة
  11. 11
    Twice-daily, Nebulized Ensifentrine Significantly Improves Lung Function: Sub-group Analysis in the Phase 3 Trial ENHANCE-1

    المؤلفون: T.M. Siler, T. Rheault, T. Bengtsson, K. Rickard

    المصدر: C40. CLINICAL TRIALS AND NOVEL INTERVENTIONS IN COPD.

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::7177946d4bf766f9fe941245f3752050
    https://doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5004

    View record in OpenAIRE

    أضف إلى المفضلة
  12. 12
    Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Improves Lung Function, Symptoms, Quality of Life and Reduces Exacerbation Rate and Risk in the Enhance-1 Phase 3 Trial of Ensifentrine in COPD

    المؤلفون: F.C. Sciurba, R.A.A. Wise, T. Rheault, T. Bengtsson, K. Rickard

    المصدر: C40. CLINICAL TRIALS AND NOVEL INTERVENTIONS IN COPD.

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::b1e38290c91fb64316903acd8a1a28fe
    https://doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5006

    View record in OpenAIRE

    أضف إلى المفضلة
  13. 13
    Academic Journal
    The Diverse Communities of a Community Choir: Fostering a Sustainable System

    المؤلفون: McCoy, K. Rickard

    المصدر: The Choral Journal, 2013 Jun 01. 53(11), 20-31.

    URL الوصول: https://www.jstor.org/stable/43051893


    أضف إلى المفضلة
  14. 14
    ExoClock project II: A large-scale integrated study with 180 updated exoplanet ephemerides

    المؤلفون: A. Kokori, A. Tsiaras, B. Edwards, M. Rocchetto, G. Tinetti, L. Bewersdorff, Y. Jongen, G. Lekkas, G. Pantelidou, E. Poultourtzidis, A. Wünsche, C. Aggelis, V. K. Agnihotri, C. Arena, M. Bachschmidt, D. Bennett, P. Benni, K. Bernacki, E. Besson, L. Betti, A. Biagini, P. Brandebourg, M. Bretton, S. M. Brincat, M. Caló, F. Campos, R. Casali, R. Ciantini, M. V. Crow, B. Dauchet, S. Dawes, M. Deldem, D. Deligeorgopoulos, R. Dymock, T. Eenmäe, P. Evans, N. Esseiva, C. Falco, S. Ferratfiat, M. Fowler, S. R. Futcher, J. Gaitan, F. Grau Horta, P. Guerra, F. Hurter, A. Jones, W. Kang, H. Kiiskinen, T. Kim, D. Laloum, R. Lee, F. Lomoz, C. Lopresti, M. Mallonn, M. Mannucci, A. Marino, J.-C. Mario, J.-B. Marquette, J. Michelet, M. Miller, T. Mollier, D. Molina, N. Montigiani, F. Mortari, M. Morvan, L. V. Mugnai, L. Naponiello, A. Nastasi, R. Neito, E. Pace, P. Papadeas, N. Paschalis, C. Pereira, V. Perroud, M. Phillips, P. Pintr, J.-B. Pioppa, A. Popowicz, M. Raetz, F. Regembal, K. Rickard, M. Roberts, L. Rousselot, X. Rubia, J. Savage, D. Sedita, D. Shave-Wall, N. Sioulas, V. Školník, M. Smith, D. St-Gelais, D. Stouraitis, I. Strikis, G. Thurston, A. Tomacelli, A. Tomatis, B. Trevan, P. Valeau, J.-P. Vignes, K. Vora, M. Vrašťák, F. Walter, B. Wenzel, D. E. Wright, M. Zíbar

    المساهمون: Astrophysique Interprétation Modélisation (AIM (UMR_7158 / UMR_E_9005 / UM_112)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut national des sciences de l'Univers (INSU - CNRS)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Société Astronomique de France (SAF), Laboratoire d'Astrophysique de Bordeaux [Pessac] (LAB), Université de Bordeaux (UB)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)

    المصدر: The Astrophysical Journal Supplement Series
    The Astrophysical Journal Supplement Series, 2022, 258, ⟨10.3847/1538-4365/ac3a10⟩

    مصطلحات موضوعية: Earth and Planetary Astrophysics (astro-ph.EP), Amateur astronomy, [SDU.ASTR]Sciences of the Universe [physics]/Astrophysics [astro-ph], [SDU]Sciences of the Universe [physics], Space and Planetary Science, Exoplanets, FOS: Physical sciences, Astronomy and Astrophysics, Transit photometry, Ephemerides, Transit photometry, Ephemerides, Exoplanets, Amateur astronomy, Astrophysics - Earth and Planetary Astrophysics

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c603d0e5ecc518a227194cfe0d489ee5
    http://hdl.handle.net/2158/1258593

    View record in OpenAIRE

    أضف إلى المفضلة
  15. 15
    Safety of Dual PDE3/4 Inhibitor Ensifentrine Added to Tiotropium: Gastrointestinal and Cardiovascular Adverse Events from a Four-Week Randomized, Controlled Trial

    المؤلفون: K. Rickard, T. Rheault, T. Bengtsson

    المصدر: TP40. TP040 COPD CLINICAL TRIALS AND THERAPIES.

    مصطلحات موضوعية: medicine.medical_specialty, Randomized controlled trial, law, business.industry, Internal medicine, Phosphodiesterase 3, Medicine, Adverse effect, business, law.invention

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::003f0b151ef242f203477083cf7c9065
    https://doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a2255

    View record in OpenAIRE

    أضف إلى المفضلة
  16. 16
    Cardiovascular Safety Profile of Ensifentrine in Patients with COPD: Results from Two Four-Week, Dose-Ranging, Randomized, Placebo-Controlled Trials

    المؤلفون: T. Bengtsson, T. Rheault, K. Rickard

    المصدر: TP40. TP040 COPD CLINICAL TRIALS AND THERAPIES.

    مصطلحات موضوعية: medicine.medical_specialty, COPD, Cardiovascular safety, business.industry, Internal medicine, Medicine, In patient, business, Placebo, medicine.disease

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::c4d990ab7736f162a9259a020efce006
    https://doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a2256

    View record in OpenAIRE

    أضف إلى المفضلة
  17. 17
    Effect of Ensifentrine on Lung Function and Health-Related Quality of Life (QoL) by COPD Severity: Analysis from a Phase 2b Dose Ranging Study

    المؤلفون: K. Rickard, T. Bengtsson, T. Rheault

    المصدر: TP40. TP040 COPD CLINICAL TRIALS AND THERAPIES.

    مصطلحات موضوعية: Health related quality of life, COPD, medicine.medical_specialty, business.industry, Internal medicine, Medicine, Dose-ranging study, business, medicine.disease, Lung function

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::42b24ff9b7a335b8ca51d36d6b072735
    https://doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a2254

    View record in OpenAIRE

    أضف إلى المفضلة
  18. 18
    Addressing the Wicked Problem of English Learner Disproportionality by Examining Speech-Language Pathologists’ Beliefs: Applying Q Methodology to Special Education

    المؤلفون: Jennifer K Rickard

    مصطلحات موضوعية: Wicked problem, Mathematics education, Special education, Psychology

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::06d86e13067412876a4f4eb121d5be84
    https://doi.org/10.26716/redlands/doctor/2020.9

    View record in OpenAIRE

    أضف إلى المفضلة
  19. 19
    Additional Bronchodilation by Ensifentrine, A Dual PDE3/4 Inhibitor, When Combined with a LAMA/LABA in Patients with Moderate to Severe COPD

    المؤلفون: K. Rickard, T. Rheault, T. Bengtsson

    المصدر: B103. TREATMENT OF OBSTRUCTIVE LUNG DISEASE.

    مصطلحات موضوعية: Moderate to severe, medicine.medical_specialty, COPD, biology, business.industry, Phosphodiesterase 3, Lama, medicine.disease, biology.organism_classification, Internal medicine, Bronchodilation, Cardiology, Medicine, In patient, business

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::3fd149078a121c1ebc09f400b591bc9c
    https://doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a4298

    View record in OpenAIRE

    أضف إلى المفضلة
  20. 20
    Ensifentrine Provides Significant and Clinically Meaningful Bronchodilation and Quality of Life Improvement on Top of Tiotropium in Symptomatic COPD Patients in a 4-Week Dose-Ranging Study

    المؤلفون: K. Rickard, T. Bengtsson, G.T. Ferguson, E.M. Kerwin, T. Rheault

    المصدر: B93. LATE BREAKING CLINICAL TRIALS IN AIRWAY DISEASES.

    مصطلحات موضوعية: medicine.medical_specialty, Quality of life, Copd patients, business.industry, Internal medicine, Bronchodilation, Medicine, Dose-ranging study, business

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::3429a02dd8ca8fc64cd3591a4537011e
    https://doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a4213

    View record in OpenAIRE

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS – أرسل هذا البحث بالبريد الإلكتروني – حفظ البحث – جدول التنبيهات: لا شيء